# US 2021/0275556 A1 · Cannabidiol Combination Compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275556 A1
- Document ID: US20210275556A1
- Status: Published application
- Kind: A1
- Application number: 17/257,244
- Filed: 2019-07-01
- Published: 2021-09-09
- Earliest claimed: 2018-07-02
- Assignees: Companion Sciences. LLC
- Applicants: Companion Sciences. LLC
- Inventors: Golan VAKNIN; Tami Bar
- Web page: https://patentgrep.com/patent/US20210275556A1

## CPC

- A61K 31/7008: Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
- A61K 31/047: having two or more hydroxy groups, e.g. sorbitol
- A61K 31/10: Sulfides; Sulfoxides; Sulfones
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 31/658: {o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol}
- A61K 31/737: Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate (A61K31/727 takes precedence)
- A61K 36/324: Boswellia, e.g. frankincense
- A61K 36/3482: {Cannabis}
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Embodiments of the invention are directed to formulations comprising Cannabidiol (CBD) and glucosamine (Gln). Further embodiments of the invention are directed to methods of treating or preventing Arthritis, Osteoarthritis, Rheumatoid arthritis, Osteoporosis, Osteopenia, jaw pain, joint pain, knee pain, back pain, multiple sclerosis, Osteomalacia and Paget's disease of bone, wherein the method comprises administering a formulation comprising Cannabidiol (CBD) and glucosamine (Gln).

## Claims

### Claim 1

A composition comprising Cannabidiol (CBD) and Glucosamine, and/or a pharmaceutically acceptable glucosamine salt, in a pharmaceutically acceptable dosage form.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the glucosamine is in the form of a pharmaceutically acceptable salt selected from the group consisting of glucosamine sulfate, glucosamine hydrochloride, N-acetyl-glucosamine and combinations thereof.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the glucosamine is in the form of glucosamine sulfate.

### Claim 4 (depends on 1)

The composition according to claim 1, wherein the CBD is extracted from a plant source.

### Claim 5 (depends on 1)

The composition according to claim 1, wherein the CBD is synthetic or semi-synthetic.

### Claim 6 (depends on 1)

The composition according to claim 1, further comprising at least one additional active ingredient.

### Claim 7 (depends on 6)

The composition of claim 6, wherein the at least one additional active ingredient is selected from the group consisting of: Chondroitin, MSM, Boswellia serrata extract (Aflapin), and combinations thereof.

### Claim at position 8

-11. (canceled)

### Claim 12 (depends on 1)

A composition according to claim 1, for use in the treatment of at least one disease, condition, symptom or disorder associated with bone and joint diseases.

### Claim 13

(canceled)

### Claim 14

A method of treating a disease, condition, symptom or disorder associated with bone and joint diseases in a subject in need thereof; said method comprising administration of a therapeutically effective amount of a composition comprising Cannabidiol (CBD) and Glucosamine and/or a pharmaceutically acceptable glucosamine salt, in a pharmaceutically acceptable dosage form.

### Claim 15 (depends on 14)

The method of claim 14, wherein the disease is osteoarthritis.

### Claim 16 (depends on 14)

The method of claim 14, wherein the pharmaceutically acceptable glucosamine salt is glucosamine sulfate.

### Claim at position 14

17-18. (canceled)

### Claim 19 (depends on 14)

The method according to claim 14, wherein the composition further comprises at least one additional active ingredient.

### Claim 20 (depends on 19)

The method of claim 19, wherein the at least one additional active ingredient is selected from the group consisting of Chondroitin, MSM, Boswellia serrata extract (Aflapin), and combinations thereof.

### Claim 21 (depends on 14)

The method according to claim 14, wherein the CBD is administered simultaneously as the glucosamine.

### Claim 22 (depends on 14)

The method according to claim 14, wherein the CBD is administered separately from the glucosamine.

### Claim 23

A method of increasing bioavailability of glucosamine in a therapeutic formulation containing an effective amount of glucosamine for treatment of at least one disease, condition, symptom or disorder associated with bone and joint diseases, the method comprising administering Cannabidiol (CBD) in the formulation in a predetermine ratio with the glucosamine.

### Claim 24 (depends on 23)

The method of claim 23, wherein the CBD is administered simultaneously as the glucosamine.

### Claim 25 (depends on 23)

The method of claim 23, wherein the CBD is administered separately from the glucosamine.

### Claim 26 (depends on 23)

The method of claim 23, wherein the at least one disease is osteoarthritis.

### Claim 27 (depends on 23)

The method of claim 23, wherein the glucosamine is in the form of a pharmaceutically acceptable salt selected from the group consisting of glucosamine sulfate, glucosamine hydrochloride and N-acetyl-glucosamine.

### Claim at position 24

28-30. (canceled)